MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-09-2024
Alpine Immune Sciences Total Liabilities 2011-2026 | ALPN
Annual Total Liabilities Alpine Immune Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 107 M | 135 M | 81.9 M | 24.6 M | 10.3 M | 6.3 M | 6.5 M | 4.42 M | 44.3 M | 95.4 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 135 M | 4.42 M | 51.6 M |
Quarterly Total Liabilities Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.9 M | 51.9 M | 78.9 M | 83.4 M | 92.6 M | 107 M | 110 M | 116 M | 119 M | 135 M | 111 M | 116 M | 76.7 M | 81.9 M | 81.9 M | 81.9 M | 81.9 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 2.52 M | 2.52 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 135 M | 2.52 M | 56 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
705 M | $ 20.36 | -1.64 % | $ 2.57 B |  USA |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
4.35 M | $ 0.81 | -4.23 % | $ 4.42 M |  China |
 |
Axsome Therapeutics
AXSM
|
602 M | $ 164.64 | -1.05 % | $ 8.19 B | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
390 M | $ 3.7 | -3.27 % | $ 1.11 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 8.53 | -2.35 % | $ 1.39 B | Britain |
 |
Corvus Pharmaceuticals
CRVS
|
6.87 M | $ 18.0 | 0.61 % | $ 864 M | USA |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Certara
CERT
|
494 M | $ 7.28 | 3.19 % | $ 1.17 B | USA |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
36.1 M | $ 26.28 | -2.16 % | $ 704 M | USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
82.1 M | $ 1.01 | -0.49 % | $ 74.1 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Catalyst Pharmaceuticals
CPRX
|
150 M | $ 23.89 | 0.04 % | $ 2.92 B | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
387 M | $ 3.22 | -3.59 % | $ 1.15 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
104 M | $ 28.92 | -0.96 % | $ 1.68 B | USA |
 |
Champions Oncology
CSBR
|
28.6 M | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
195 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
1.04 B | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
253 M | $ 3.68 | -3.16 % | $ 116 M | France |
 |
Alector
ALEC
|
263 M | $ 2.13 | -3.62 % | $ 219 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
8.78 M | $ 15.77 | -1.81 % | $ 783 M | Britain |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
7.8 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
15.8 M | $ 4.25 | 2.04 % | $ 302 M | USA |
 |
Teligent, Inc.
TLGT
|
198 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
47.4 M | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
211 M | $ 14.2 | 1.9 % | $ 5.89 B |  Irlanda |